Works matching IS 13419625 AND DT 2022 AND VI 27 AND IP 12

Results: 14
    1

    List of reviewers 2021–2022.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1916, doi. 10.1007/s10147-022-02254-1
    Publication type:
    Article
    2
    3
    4
    5
    6

    A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1881, doi. 10.1007/s10147-022-02247-0
    By:
    • Campos, Susana;
    • Matulonis, Ursula;
    • Berlin, Suzanne;
    • Horowitz, Neil;
    • Liu, Joyce;
    • Krasner, Carolyn;
    • Hang, Lee;
    • Zarwan, Corrine;
    • Barry, William;
    • Colella, Tina;
    • Whalen, Christen;
    • Shoni, Melina;
    • Lundquist, Christine;
    • Birrer, Michael J.;
    • Penson, Richard
    Publication type:
    Article
    7

    Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1874, doi. 10.1007/s10147-022-02246-1
    By:
    • Shoji, Tadahiro;
    • Takatori, Eriko;
    • Nagasawa, Takayuki;
    • Kagabu, Masahiro;
    • Baba, Tsukasa;
    • Shigeto, Tatsuhiko;
    • Matsumura, Yukiko;
    • Shimizu, Dai;
    • Terada, Yukihiro;
    • Seino, Manabu;
    • Ohta, Tsuyoshi;
    • Nagase, Satoru;
    • Shigeta, Shogo;
    • Tokunaga, Hideki;
    • Shimada, Muneaki;
    • Kaiho-Sakuma, Michiko;
    • Furukawa, Shigenori;
    • Soeda, Shu;
    • Watanabe, Takafumi;
    • Takahashi, Fumiaki
    Publication type:
    Article
    8
    9
    10

    Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1859, doi. 10.1007/s10147-022-02243-4
    By:
    • Matsuoka, Hiroshi;
    • Yamada, Takeshi;
    • Ohta, Ryo;
    • Yoshida, Yoichiro;
    • Watanabe, Tatsuyuki;
    • Takahashi, Makoto;
    • Kosugi, Chihiro;
    • Fukazawa, Atsuko;
    • Kuramochi, Hidekazu;
    • Matsuda, Akihisa;
    • Sonoda, Hiromichi;
    • Yoshida, Hiroshi;
    • Hasegawa, Suguru;
    • Sakamoto, Kazuhiro;
    • Otsuka, Toshiaki;
    • Hirata, Keiji;
    • Koda, Keiji
    Publication type:
    Article
    11
    12
    13

    Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1828, doi. 10.1007/s10147-022-02232-7
    By:
    • Sugawara, Shunichi;
    • Kondo, Masashi;
    • Yokoyama, Toshihide;
    • Kumagai, Toru;
    • Nishio, Makoto;
    • Goto, Koichi;
    • Nakagawa, Kazuhiko;
    • Seto, Takashi;
    • Yamamoto, Nobuyuki;
    • Kudou, Kentarou;
    • Asato, Takayuki;
    • Zhang, Pingkuan;
    • Ohe, Yuichiro
    Publication type:
    Article
    14

    First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 12, p. 1805, doi. 10.1007/s10147-022-02233-6
    By:
    • Takahashi, Shunji;
    • Oridate, Nobuhiko;
    • Tanaka, Kaoru;
    • Shimizu, Yasushi;
    • Fujimoto, Yasushi;
    • Matsumoto, Koji;
    • Yokota, Tomoya;
    • Yamazaki, Tomoko;
    • Takahashi, Masanobu;
    • Ueda, Tsutomu;
    • Hanai, Nobuhiro;
    • Yamaguchi, Hironori;
    • Hara, Hiroki;
    • Yoshizaki, Tomokazu;
    • Yasumatsu, Ryuji;
    • Nakayama, Masahiro;
    • Shiga, Kiyoto;
    • Fujii, Takashi;
    • Mitsugi, Kenji;
    • Takahashi, Kenichi
    Publication type:
    Article